VintaBio™ Files Patents for Scalable Manufacturing Platform Built to Accelerate Gene Therapy Commercialization
VintaBio™, a technology-forward company, announced today that it has filed provisional patents with the US Patent Office describing its novel approach to manufacturing biotherapeutics using adherent culturing methods in a small-scale process.
VintaBio Presents Data Demonstrating High-Efficiency AAV Vector Production Using Proprietary VintaProcess™ at 2025 ASGCT Annual Meeting
VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and productivity of its proprietary VintaProcess™ at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.
VintaBio Unveils New Data Showcasing Scalable AAV Perfusion Manufacturing Platform with High Full Capsid Yield at 2025 ASGCT Annual Meeting
VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present transformative data on its proprietary VintaProcess™, an advanced intensified adherent viral vector manufacturing platform. The data will be shared during a poster session at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New Orleans, LA, on May 13-17, 2025. The VintaBio team will also be meeting with conference attendees at booth 808.
